Mitigation of Human-Pathogenic Fungi That Exhibit Resistance to Medical Agents: Can Clinical Antifungal Stewardship Help?

Claire M Hull; Nicola J Purdy; Suzy C Moody


Future Microbiol. 2014;9(3):307-325. 

In This Article

Antimicrobial Stewardship & Multidrug Resistant Human-Pathogenic Fungi

Clinical antimicrobial stewardship in hospitals and primary healthcare settings is an essential facet of drug delivery that underpins efforts to mitigate the emergence of antibiotic resistance on a worldwide scale.[1] It is central to prolonging the effectiveness of currently available antimicrobials, improving patient outcomes and reducing the healthcare and societal costs associated with infectious disease.[2] However, despite global and increasing concern regarding the healthcare burden and spectrum of diseases caused by human-pathogenic fungi, until recently, the terms 'antimicrobial' and 'antibiotic stewardship' have been used almost synonymously. Now, as awareness, new knowledge and further inquiry into the role of fungi in human health and disease continue to grow,[3–7,106] the need to fully appraise the targets and future trajectory of antifungal stewardship initiatives is clear.[8–10]